Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01698918
Title Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

Her2-receptor negative breast cancer

Therapies

Everolimus + Exemestane

Everolimus + Letrozole

Age Groups: adult
Covered Countries USA | FRA | ESP


No variant requirements are available.